Skip to main content
Premium Trial:

Request an Annual Quote

Veracyte Prices $180M Public Stock Offering

NEW YORK – Veracyte said after the market closed Tuesday afternoon that it has priced a public offering of 6 million shares of its common stock at $30 per share. It expects gross proceeds of around $180 million.

Veracyte will use the net proceeds from the offering for working capital and other general corporate purposes. The firm may also use part of the proceeds to acquire or invest in complementary businesses, technologies, or other assets.

Goldman Sachs and SVB Leerink are joint lead book-running managers for the offering, while William Blair is a book-running manager and BTIG, Needham, and Lake Street Capital Markets are co-managers.

Veracyte has granted underwriters a 30-day stock option to purchase up to an additional 900,000 shares of its common stock at the public offering price. The offering is expected to close around Aug. 7, 2020, the firm said.

Veracyte's stock was down about 7 percent at $30.00 in Wednesday morning trading on the Nasdaq.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.